Mircera Continuous Erythropoiesis Receptor Activator: Updated Phase III data

Updated data from the international Phase III PROTOS trial in CKD patients on dialysis showed that once-monthly dose of

Read the full 194 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE